Squarepoint
COYA icon

Squarepoint’s Coya Therapeutics COYA Stock Holding History

Squarepoint’s Portfolio COYA Stock Details COYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$195K Sell
33,260
-7,205
-18% -$33.4K ﹤0.01% 4075
2026
Q1 		$159K Sell
40,465
-24,685
-38% -$115K ﹤0.01% 4004
2025
Q4 		$378K Buy
+65,150
New +$396K ﹤0.01% 3436

Other funds holding COYA

DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.8B AUM 23.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Squarepoint's COYA Position: Q2 2026 in Review

Squarepoint reduced its Coya Therapeutics (COYA) stake by 18% in Q2 2026, selling an estimated $33.4K and leaving 33,260 shares worth $195K. The position accounts for ﹤0.01% of the portfolio, ranked #4075.

Squarepoint first reported a position in COYA in Q4 2025 and has held it in 3 quarters since. The position peaked at $378K in Q4 2025. 54 funds tracked by Wall St. Rank hold COYA as of Q2 2026.

  • Squarepoint held 33,260 shares of Coya Therapeutics worth $195K as of Q2 2026.
  • Squarepoint sold 7,205 Coya Therapeutics shares in Q2 2026, an estimated $33.4K.
  • Coya Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4075 holding.
  • Squarepoint first reported a position in Coya Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Squarepoint's Coya Therapeutics position peaked at $378K in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Coya Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.